Mastocytosis pre-cytoreductive therapy infection screening: HBsAg+, anti-HCV+, HIV+, late...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-MASTOCYTOSIS-INFECTION-SCREENING`
Type	Red flag
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-MASTOCYTOSIS`
Sources	`SRC-AASLD-HBV-2024` `SRC-NCCN-SM-2025`

Red Flag Origin

Definition	Mastocytosis pre-cytoreductive therapy infection screening: HBsAg+, anti-HCV+, HIV+, latent TB — relevant before cladribine, IFN-α, or allo-HCT
Clinical direction	hold
Category	infection-screening
Shifts algorithm	ALGO-ADVSM-1L

Trigger Logic

{
  "any_of": [
    {
      "finding": "hbsag_positive",
      "value": true
    },
    {
      "finding": "hcv_antibody_positive",
      "value": true
    },
    {
      "finding": "hiv_positive",
      "value": true
    },
    {
      "finding": "latent_tb_positive",
      "value": true
    }
  ],
  "type": "composite"
}

Notes

Cladribine (purine analog) is profoundly lymphotoxic; per NCCN-SM: HBV/HCV/HIV screen mandatory before cytoreductive therapy. AASLD-HBV 2024 mandates entecavir or TAF prophylaxis for HBsAg+ on lymphocyte- depleting therapy through 12 months post-completion. Direction HOLD on cytoreduction until prophylaxis underway. STUB — requires clinical co-lead signoff.

Used By

No reverse references found in the YAML corpus.